All Updates

All Updates

icon
Filter
Regulation/policy
DEA to plan strict limits on telehealth prescribing of controlled substances
Telehealth
Sep 4, 2024
This week:
Management news
Consensys conducts layoffs citing regulatory battles and market pressure
Enterprise Blockchain Solutions
Yesterday
Management news
Consensys conducts layoffs citing regulatory battles and market pressure
Web3 Ecosystem
Yesterday
Funding
HOMEE raises USD 12 million in Series C funding to develop smart claims management platform
InsurTech: Infrastructure
Yesterday
Product updates
Snap launches simplified version of Snapchat to drive user engagement; adds new AI features
Creator Economy
Yesterday
Partnerships
Bloomreach partners with Planet to offer unified commerce personalization solution
Marketing Automation
Yesterday
Partnerships
Criteo partners with OMS providers and Salesforce to enhance retail media network solutions
Marketing Automation
Yesterday
Product updates
Basware launches Insights platform with GenAI capabilities to enhance touchless invoicing
Business Expense Management
Yesterday
Product updates
HiBob launches learning and development module Bob Learning to enhance workforce capability
Remote Work Infrastructure
Yesterday
Funding
Fingercheck raises USD 115 million in growth funding to support expansion
Remote Work Infrastructure
Yesterday
Funding
Blacklane raises USD 65 million in Series G funding to expand operations
Travel Tech
Yesterday
Sep 4, 2024

DEA to plan strict limits on telehealth prescribing of controlled substances

Regulation/policy

  • The Drug Enforcement Administration (DEA) is finalizing a proposed rule for prescribing controlled substances via telehealth, which is reportedly more restrictive than advocates hoped. The draft rule, currently under White House review, would limit telehealth prescribing of certain controlled substances and require in-person visits for some medications.

  • Recent reports suggest that the proposed rule would prohibit prescribing Schedule II substances like Adderall via telehealth without an initial in-person visit. For Schedule III-V substances, only 50% of prescribing could be done online, with the other half requiring in-person visits.

  • In response, telehealth advocacy groups seek a two-year extension of current flexibilities. They are gathering signatures for letters to Congress and the White House, arguing that the DEA lacks time to finalize a rule before current waivers expire at the end of 2024.

  • Some lawmakers, including Senator Mark Warner, have criticized the reported restrictions, calling on the DEA to lift some of these proposed limitations on telemedicine prescribing.

  • Analyst QuickTake : In May 2023 , the DEA temporarily extended the emergency flexibilities granted to telehealth companies during the Covid-19 pandemic for six months, only to withdraw the proposed limitations at the end of the extension period after receiving an unprecedented 38,000 public comments. The rules still do not appear to meet the industry's needs, and after a year, finding common ground is still a long way off.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.